Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Blakey

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Biochemical Society Transactions|November 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour diseaseD C Blakey, P J Burke, D H Davies, et al.
Cancer Research|December 15, 1988
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cellsD C Blakey, D N Skilleter, R J Price, et al.
Journal of Medicinal Chemistry|December 22, 1995
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)C J Springer, R Dowell, P J Burke, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
Journal of the National Cancer Institute|November 1, 1987
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutantsP E Thorpe, D C Blakey, A N Brown, et al.
Cell Biophysics|January 1, 1993
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrugD C Blakey, B E Valcaccia, S East, et al.
Cancer Research|November 15, 1987
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivoP E Thorpe, P M Wallace, P P Knowles, et al.
British Journal of Cancer|November 1, 1995
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugsD C Blakey, D H Davies, R I Dowell, et al.
British Journal of Cancer|September 18, 2008
Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanomaM H A M Fens, K J Hill, J Issa, et al.
Journal of Medicinal Chemistry|March 1, 1996
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide linkR I Dowell, C J Springer, D H Davies, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Biochemical Society Transactions|November 1, 1995
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour diseaseD C Blakey, P J Burke, D H Davies, et al.
Cancer Research|December 15, 1988
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cellsD C Blakey, D N Skilleter, R J Price, et al.
Journal of Medicinal Chemistry|December 22, 1995
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)C J Springer, R Dowell, P J Burke, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
Journal of the National Cancer Institute|November 1, 1987
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutantsP E Thorpe, D C Blakey, A N Brown, et al.
Cell Biophysics|January 1, 1993
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrugD C Blakey, B E Valcaccia, S East, et al.
Cancer Research|November 15, 1987
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivoP E Thorpe, P M Wallace, P P Knowles, et al.
British Journal of Cancer|November 1, 1995
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugsD C Blakey, D H Davies, R I Dowell, et al.
British Journal of Cancer|September 18, 2008
Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanomaM H A M Fens, K J Hill, J Issa, et al.
Journal of Medicinal Chemistry|March 1, 1996
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide linkR I Dowell, C J Springer, D H Davies, et al.
Pageof 4